Adaptimmune Therapeutics plc - American Depositary Shares (NQ:ADAP)

0.0549 UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 27, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Adaptimmune Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 28, 2025

Via Benzinga

Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds

July 28, 2025

Tecelra will continue to be available to patients without interruption US WorldMeds plans to bring lete-cel to market and will...

Via Newsfile

This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗

June 26, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

June 12, 2025

Via Benzinga

Demystifying Adaptimmune Therapeutics: Insights From 4 Analyst Reviews ↗

November 27, 2024

Via Benzinga

Earnings Scheduled For November 13, 2024 ↗

November 13, 2024

Via Benzinga

Forecasting The Future: 6 Analyst Projections For Adaptimmune Therapeutics ↗

May 14, 2025

Via Benzinga

Adaptimmune Reports Q1 Financial Results and Provides Business Update

May 13, 2025

TECELRA® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced$4.0 million Tecelra net sales in...

Via Newsfile

A Look Ahead: Adaptimmune Therapeutics's Earnings Forecast ↗

May 12, 2025

Via Benzinga

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

May 07, 2025

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...

Via Newsfile

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 23, 2025

Via Benzinga

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 04, 2025

Via Benzinga

Tuesday's after hours session: top gainers and losers ↗

April 01, 2025

Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.

Via Chartmill

What Analysts Are Saying About Adaptimmune Therapeutics Stock ↗

April 01, 2025

Via Benzinga

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

March 20, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Via Chartmill

Here are the top movers in Thursday's session. ↗

March 20, 2025

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Via Chartmill

Top movers in Thursday's session ↗

March 20, 2025

Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 20, 2025

Via Benzinga

Which stocks are gapping on Thursday? ↗

March 20, 2025

The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

Dow Gains Over 100 Points; Accenture Shares Plunge After Q2 Results ↗

March 20, 2025

Via Benzinga

Topics Stocks

Adaptimmune Provides Q4 and Full Year 2024 Business Update

March 20, 2025

TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and...

Via Newsfile

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

March 12, 2025

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...

Via Newsfile

Earnings Scheduled For March 20, 2025 ↗

March 20, 2025

Via Benzinga

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

January 30, 2025

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working...

Via Newsfile

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

January 13, 2025

The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other...

Via Newsfile

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

December 19, 2024

Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31,...

Via Newsfile

Topics Initial Public Offering

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

December 02, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company...

Via Newsfile

Adaptimmune Reports Q3 2024 Financial and Business Updates

November 13, 2024

Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed...

Via Newsfile

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

November 13, 2024

42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-celResults include six complete responses...

Via Newsfile

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.